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and improved outcome in an established humanized mouse
model of allo HCT.
Methods: Sublethally irradiated RAG2-/- gc-/- mice were trans-
planted with 30 million human PBMCs (huPBMCs). Vedolizumab
or control IgG was given intraperitoneally at a dose of 4mg/kg
body weight on day -1 and day +15 (preventive approach) or
day +8 and day +22 (therapeutic approach). Time points were
chosen in order to start a4b7 blockade prior to clinical onset of
GVHD (preventive approach) and when animals started to get
significantly suffer from GVHD (therapeutic approach). As non-
GVHD controls, animals received sublethal irradiation without
huPBMCs administration and received VDZ or control IgG to
assess for direct conditioning and VDZ toxicity.
Results: HuPBMC CD45 splenocyte analysis on day +28 after
infusion demonstrated strong human leukocyte engraft-
ment with more than 80% of spleen cells being huCD45
positive. Both preventive and therapeutic administration of
Vedolizumab resulted in significantly improved survival in
HuPBMC treated recipients when compared to IgG treated
GVHD controls at week 8 (62.6% Vs 12.5% and 50% Vs 12.5%
respectively). All recipients, which did not receive huPBMCs
survived, indicating VDZ safety in this model. Clinical GVHD
scores after day 21 after transplant were significantly lower
in VDZ huPBMCs treated animals until end of analysis com-
pared to control-treated recipients using both the preven-
tive and therapeutic approaches, along with significant
decreases in GI tract pathology scores on day +28. No dif-
ferences in pathology were seen in liver or lung at this
time point. Serum cytokine analysis revealed decreases in
TNF (p<0.05) and IFNg (p<0.05) levels in Vedolizumab
therapeutically treated recipients on day +28 and in TNF
(p<0.05) in preventively treated recipients compared to
control treated animals. Histopathologic analysis of T cell
infiltration of small intestine and colon by immunohis-
tochemistry for CD3 antibody revealed significantly lower
infiltration of human T cells in VDZ huPBMCs treated group
(p<0.05).
Conclusion: Vedolizumab reduces the severity of intestinal
GVHD by targeting donor T cell migration into the intestinal
tract both when given early prior to onset of clinical disease
and given at later time point, and improves overall survival
both in the preventive and therapeutic setting. Given these
promising results, targeting T cell homing with VDZ potentially
presents a novel option for the management of intestinal
GVHD.Figure 1. Patients' perception about their prognosis according to level of
information.HEALTH SERVICES
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Introduction: The lack of patients’ understanding of diagnosis,
prognosis and treatment options can complicate an informed
decision to undergo HSCT. Our outpatient-based HSCT unit in
Northeast Mexico performs near 100 transplants/year. Wetreat patients from different regions and sociocultural back-
grounds, representing a challenge during the initial evaluation.
Objective: We aim to assess knowledge and attitudes in HSCT
candidates regarding their diagnosis, prognosis and treatment
including HSCT.
Methods: Since December 2017, all new adult patients visiting
our unit were asked to complete a 36-element survey prior to
initial consultation. Questions were taken from a published
questionnaire with face validity translated into Spanish, evalu-
ating patients’ perception related to diagnosis, prognosis, and
treatment options including HSCT.
Patients were grouped according to transplant type, place of
residence, education, insurance and healthcare provider. We
analyzed answers according to patients’ perceived level of
knowledge regarding HSCT (with vs without enough informa-
tion to make a decision) and disease risk index (DRI). Variables
were analyzed using Chi-squared or Mann-Whitney test.
Results: Forty-nine patients have answered the survey: 29
females (59.2%), median age 47 years (16-71). Most patients
were eligible for auto-HSCT (53.1%), 59.2% lived in another
city, 55.1% had low education level, 55.1% had public health
insurance, and 65.3% were treated in a public healthcare cen-
ter. DRI was obtained in 47 patients: high-very high (40.4%)
vs low-intermediate (59.6%). Overall, 57.1% stated to have
enough information about their diagnosis, and 53.1% about
their treatment options and HSCT. More local patients had
enough information about treatment options than those
living in a foreign city (70 vs 41.4%); p=0.048. No other differ-
ences were observed.
A higher proportion of patients who reported to have enough
information believed that HSCT might cure them compared to
those w/o enough information (92.3 vs 65.2%); p=0.019 (Fig
1). Also, 84.6% of patients with enough information expressed
to have excellent chances (80%) to be cured after HSCT, com-
pared to 52.2% of low-informed ones; p=0.008 (Fig 2). The
proportion of high-very high DRI patients that expressed to
have excellent chances of being cured with HSCT was similar
to those with low-intermediate DRI (68.4 vs 71.4%); p=0.295
(Fig 3).
Conclusion: Many patients referred to our HSCT unit lack
information regarding their disease, prognosis and treatment
options. Significantly, patients living in a foreign city were less
informed about therapeutic options than local patients. More-
over, patients who perceived to have enough information
about HSCT tended to overestimate their prognosis. Imple-
mentation of further educational strategies is mandatory to
enhance patients’ knowledge to take an informed decision for
HSCT.
